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Abstract
In the Multi-Site Clinical Assessment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome 
(MCAM), we relied on expert clinician diagnoses to enroll patients from 7 specialty clinics in the 
United States in order to perform a systematic collection of data on measures of myalgic 
encephalomyelitis (ME)/chronic fatigue syndrome (CFS). Healthy persons and those with other 
illnesses that share some features with ME/CFS were enrolled in comparison groups. The major 
objectives were to: 1) use standardized questionnaires to measure illness domains of ME/CFS and 
to evaluate patient heterogeneity overall and between clinics; 2) describe the course of illness, 
identify the measures that best correlate with meaningful clinical differences, and assess the 
performances of questionnaires as patient/person-reported outcome measures; 3) describe 
prescribed medications, orders for laboratory and other tests, and management tools used by 
expert clinicians to care for persons with ME/CFS; 4) collect biospecimens for future hypothesis 
testing and for evaluation of morning cortisol profiles; and 5) identify measures that best 
distinguish persons with ME/CFS from those in the comparison groups and detect subgroups of 
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persons with ME/CFS who may have different underlying causes. Enrollment began in 2012 and is 
planned to continue in multiple stages through 2017. We present the MCAM methods in detail, 
along with an initial description of the 471 patients with ME/CFS who were enrolled in stage 1.
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chronic fatigue syndrome; myalgic encephalomyelitis; patient-reported outcome measures; study 
methods
Chronic fatigue syndrome (CFS) has been known by a variety of names, including 
postinfectious fatigue, myalgic encephalomyelitis (ME), and, more recently, systemic 
exertion intolerance disease. The condition, hereafter referred to as ME/CFS, is a chronic 
multisystem illness characterized by reduced functioning associated with fatigue that is not 
due to ongoing exertion and not significantly improved by rest. Minimal mental or physical 
exertion may trigger relapse (termed postexertional malaise). Additional core or common 
symptoms include unrefreshing sleep, cognitive problems, increased symptoms when 
standing, and pain; however, patients may experience numerous other symptoms.
ME/CFS is a significant public health problem. Estimates from population-based studies 
indicate that at least 1 million Americans suffer from ME/CFS (1–3). Patients, their families, 
their employers, and society all bear significant costs associated with ME/CFS, which are 
estimated to be $18–$51 billion annually in the United States ($9–$14 billion in direct 
medical costs and $9–$37 billion in lost productivity) (4–6). Yet, ME/CFS remains poorly 
understood by the health-care community, and patients face significant barriers to receiving 
the care that they need (7).
Although a number of biologic abnormalities have been found in some groups of people 
with ME/CFS, to date, none is sufficiently unique or characteristic to be diagnostic. A 
number of case definitions based on expert opinion have been used in research and for 
diagnosis (8–11). Although the case definitions share many features, they differ in the 
number and type of required symptoms. Because studies of ME/CFS use 1 or more case 
definitions as entry criteria, developing a data-driven case definition has been challenging. In 
addition, none of the case definitions provides sufficient detail on methods for 
operationalizing their applications, so differences in details of how the case definition is 
applied need to be considered (12). Measures of ME/CFS that are reliable and reflect 
meaningful clinical differences are needed for diagnosis and would also be important when 
describing the natural history of the illness, categorizing and measuring changes in response 
to interventions, and identifying patient populations with similar illness profiles for basic 
research and clinical trials. Systematically studying patients with ME/CFS identified from 
multiple specialized clinics would provide a mechanism to evaluate measures of ME/CFS. 
When the ME/CFS patients are identified by clinicians with recognized expertise in 
diagnosing and treating the condition, the resulting data could also inform case definition 
questions. In the present article, we describe the Multi-Site Clinical Assessment of Myalgic 
Encephalomyelitis/Chronic Fatigue Syndrome (MCAM), a multisite clinical study of 
ME/CFS that was initiated and funded by the Centers for Disease Control and Prevention 
(CDC).
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MCAM was designed to enroll and follow ME/CFS patients recruited from multiple 
specialized clinics in order to facilitate systematic collection of data on measures of their 
illness. A key feature was reliance on the clinical experience of physicians who specialize in 
the identification and management of ME/CFS patients rather than on a prespecified case 
definition. Healthy persons and those with other illnesses that share some features with 
ME/CFS were enrolled in comparison groups. In MCAM, our principal objectives were to:
1. Use standardized questionnaires to measure illness domains of ME/CFS and to 
evaluate patient heterogeneity overall and between clinics;
2. Describe the course of illness, identify measures that best correlate with 
meaningful clinical differences, and assess the performances of questionnaires as 
patient/person-reported outcome measures;
3. Describe prescribed medications, orders for laboratory and other tests, and 
management tools used by expert clinicians to care for persons with ME/CFS;
4. Collect biospecimens for future hypothesis testing and for evaluation of morning 
cortisol profiles; and
5. Identify measures that best distinguish persons with ME/CFS from those in the 
comparison groups and determine subgroups of persons who have ME/CFS with 
different underlying causes.
In the present article, we provide the reader with detailed information on the design of this 
multisite clinical investigation of ME/CFS, as well as descriptive information about 
participants enrolled in stage 1.
METHODS
Study overview
MCAM was initiated in 2012 and is anticipated to continue in multiple stages through 2017. 
In the first stage (stage 1), investigators enrolled only participants with ME/CFS. In stage 2, 
researchers collected follow-up information from those enrolled in stage 1 and recruited 2 
comparison groups: a group of healthy controls and an ill comparison group comprising 
patients with other chronic illnesses (e.g., fibromyalgia, rheumatoid arthritis, multiple 
sclerosis, and cardiovascular disease). Biologic samples were also collected. In subsequent 
stages, an effort was made to recruit ME/CFS patients who had been ill for a short time (<2 
years; i.e., incident cases) and those severely affected by ME/CFS (home-bound). The 
home-bound ME/CFS patients met the following criteria, which were agreed upon by the 
study clinicians: 1) bedfast or severely house-bound; 2) activity level less than 10% of prior 
levels; and 3) unable to come to the office without severe consequences. Beginning with 
stage 2, we permitted enrollment of new participants in the ME/CFS and control groups to 
replace those who dropped out or were lost to follow-up. The replacement participants had 
to complete baseline forms in addition to providing any data or biologic samples that were 
required for the stage at which they were enrolled. Because enrollment began at different 
times for the ME/CFS, comparison, incident ME/CFS, and home-bound ME/CFS cohorts, 
the study is considered to have a rolling cohort design.
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Study sites
Recruitment and enrollment were conducted through 7 clinics with specialized expertise in 
and experience with diagnosis and management of ME/CFS: Mount Sinai Beth Israel, New 
York, New York; Institute for Neuro Immune Medicine, Miami and Fort Lauderdale, 
Florida; Bateman Horne Center, Salt Lake City, Utah; Hunter-Hopkins Center, Charlotte, 
North Carolina; Open Medicine Clinic, Mountain View, California; Richard Podell N. 
Medical, Summit, New Jersey; and Sierra Internal Medicine, Incline Village, Nevada. Five 
clinics (Bateman Horne Center, Hunter-Hopkins Center, Open Medicine Clinic, Richard N. 
Podell Medical, and Sierra Internal Medicine) participated through the coordination of the 
Open Medicine Institute Consortium (Mountain View, California). The present study was 
approved by the institutional review boards of the CDC, Open Medicine Institute 
Consortium, Mount Sinai Beth Israel, and Institute for Neuro Immune Medicine.
Enrolled study groups
All participants were enrolled after providing informed consent. ME/CFS patients were 
those between 18 and 70 years of age who had been diagnosed with CFS, ME, or 
postinfectious fatigue or who were managed as were other ME/CFS patients in the clinical 
practice. Each clinician determined patient eligibility using his or her clinical expertise with 
the condition; patients were not required to fit a specific case definition. The exclusion 
criteria were onset of illness at an age older than 62 years, human immunodeficiency virus 
infection, current pregnancy, or dementia. The study was conducted in English, and 
participants had to be able to read written forms and computer screens at an eighth grade 
level; however, no formal testing of reading ability was performed.
Participants enrolled as healthy controls were individuals between 18 and 70 years of age 
who were in good health and had no history of ME/CFS and no other active illnesses. They 
were enrolled on an approximately 1:1 basis with ME/CFS patients and were matched on 
sex and age (±5 years). Participants enrolled into the ill comparison group were those 
between 18 and 70 years of age who had physician-diagnosed fibromyalgia (without ME/
CFS), rheumatoid arthritis, Lyme disease, or cardiovascular disease, with a minimum of 50 
participants enrolled for each diagnosis. Clinics recruited participants in the comparison 
groups in a variety of ways, including by posting flyers in the clinics, distributing flyers in 
the communities, and recruiting from other primary care or specialty clinics in the same 
institutions or networks.
Clinic staff or study coordinators telephoned patients who were identified by the clinician or 
through clinical record as potentially eligible for study participation to explain the study to 
them and to obtain verbal consent for eligibility screening and medical record data 
abstractions before the clinic visit. Those who were eligible and interested in participating 
provided signed informed consent via a web-based system (OpenMedNet, Open Medicine 
Institute) or a paper form at the next clinic visit. Each participant was given a unique study 
identification number that was used in coding of all data and samples. The linkage of study 
identification number to personal identifiers was maintained by each clinic and not shared 
with the CDC. Access to identifiable patient records was limited to the study staff at each 
clinic and, for those clinics participating through the Open Medicine Institute Consortium, 
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the Open Medicine Institute coordinating center. No identifying information was recorded 
on any materials shared with the CDC.
Medical record abstraction
To minimize the burden of the study on the participants, authorized study personnel 
reviewed participant medical records to abstract information. Forms were developed to 
standardize collection of data on basic demographic characteristics (age, sex, race, ethnicity, 
marital status, employment, insurance status, and educational level); history of ME/CFS 
(date of diagnosis, age at diagnosis, symptoms, and date of symptom onset); medical history 
(major illnesses before and after 21 years of age, surgeries, major injuries and 
hospitalizations and age at those events, allergies and sensitivities, and review of organ 
systems); family history (mother, father, siblings, and children); medication use (prescription 
and over-the-counter drugs; supplements; herbal, homeopathic and health food preparations; 
dose and dosing schedule of each; date initiated; and reason for taking); infection and 
immunization history; and laboratory and test results at the first and most recent visits to the 
clinic (e.g., complete blood count with differential, blood chemistry, C-reactive protein 
concentration, antinuclear antibody level, rheumatoid factor level, thyroid-stimulating 
hormone level, free thyroxine concentration, urinalysis, electrocardiogram, sleep study, and 
tilt test). In addition, the clinic intake form was copied, stripped of patient identifiers, and 
scanned to make a portable document format (PDF) copy for data transfer. Data abstractions 
forms (other than clinical intake forms) are included in the Web Appendix (available at 
http://aje.oxfordjournals.org/). The study was designed not only to retrospectively abstract 
participants’ medical records before their study enrollment but also to prospectively collect 
detailed clinical and epidemiologic data.
Measures of ME/CFS illness domains
Standardized questionnaires were used to collect data on symptoms and to measure fatigue, 
function, pain, sleep, anxiety, depression, quality of life, and illness impact (11, 13–32). The 
questionnaires are listed in Table 1, with forms and scoring available from the references 
cited. Anxiety and depression scales were self-administered by participants in the clinic and 
completed during the visit. All other forms were provided to the patients to complete as they 
were able, either online or on paper. The study allowed some flexibility in the timeline for 
completing these forms because the severity of each patient’s illness could vary from day to 
day. Instead, the dates and times at which each form was started and completed were noted. 
Family members or clinic personnel provided assistance to patients if necessary. Forms were 
to be completed within 2 weeks of the visit to clinic.
The complete set of forms was collected at the enrollment visit; however, for follow-up, only 
interim changes in medical history, family history, and medication use were recorded. 
Likewise, the Brief Pain Inventory (long form) (24) and questionnaires on depression and 
anxiety were omitted at follow-up, and the CDC Symptom Inventory for chronic fatigue 
syndrome (13) and questions from DePaul Symptom Questionnaire (11) were shortened to 
reduce the burden on study participants. Some other forms were modified to adapt to the 
differing needs of cohorts, such as home-bound patients.
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Flow of clinic visit used for study enrollment
Clinic personnel obtained informed consent (if not given previously) and reviewed 
questionnaires completed by patients at home (Table 1) to check for completeness and to 
resolve any contradictory or missing information. Clinic staff reviewed the abstracted 
information on medical history, family history, and medication use with the participants to 
verify the data and add any missing information. Participants were also asked to complete 
the 3 forms reserved for completion at the clinic (28–32), and clinic staff were available to 
provide assistance. Each patient underwent a complete physical examination if one had not 
been performed within 1 year. To increase standardization of the physical examination, a 
study form was used to record the results (Web Appendix). The remainder of the clinic visit 
was devoted to the patient’s routine clinical care.
Follow-up clinic visits
Follow-up visits kept the same general flow as the enrollment visit. Patients completed the 
questionnaires at home within 1 week of the clinic visit, and some of the questionnaires 
were omitted. Biologic samples collected at home (saliva) were given to clinic personnel, 
and blood samples were drawn. (Biologic samples were collected at the first visit for all 
participants enrolled in stage 2 and subsequent stages.) The remainder of the clinic visit was 
devoted to the patient’s routine clinical care. Follow-up is planned annually (10–14 months) 
to coincide with return clinic appointments. The number of follow-up visits for each 
participant will vary depending on the stage at first enrollment. Persons enrolled at stage 1 
would have a maximum of 5 follow-up visits.
Biologic samples
To assure quality and comparability of biologic samples, a standard operating procedure for 
collection, labeling, storage, and handling was developed by the CDC’s Molecular 
Epidemiology Laboratory. Laboratory staff reviewed the standard operating procedure with 
study personnel at each clinic to be sure that the steps were clear. Each clinic had the written 
standard operating procedure readily available onsite to guide collection. The CDC provided 
components for the saliva collection kits, blood collection tubes, and shipping supplies to the 
clinics.
Saliva—Participants were asked to collect 4 saliva samples at home to allow measurement 
of cortisol and α-amylase awakening response (immediately after awakening while still in 
bed and 30, 45, and 60 minutes after awakening). Clinic personnel mailed saliva collection 
kits to patients approximately 2 weeks before their clinic visits. Each kit included written 
instructions for collection, 4 individually wrapped SalivaBio Oral Swabs (Salimetrics, 
Carlsbad, California), 4 swab storage tubes, 1 specimen transport bag, 1 cold pack, 1 thermal 
bag, and a saliva collection form (to record time at which the participant went to sleep, the 
usual time at which she or he went to sleep, the times of saliva collection, and quality of 
sleep during the night before collection). The clinic called each patient after his or her kit 
was received to review all parts of the kit, describe the process for collecting samples, and 
answer any questions. Patients were asked to collect samples on awakening in the morning 
before the day of the clinic visit. Collection could be performed as many as 3 days before the 
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clinic visit to avoid cortisol changes due to stressful travel days. Patients placed saliva 
samples in specimen transport bag, added the saliva collection form to outer pouch of the 
transport bag, and sealed the bag. The bagged samples were placed in the thermal bag and 
kept in a refrigerator until the day of the clinic visit, when the chilled cold pack was added to 
thermal bag to keep contents cool during travel. When patients came to the clinic, study 
personnel reviewed the specimens, correlated numbers with information on the saliva 
collection form, resolved any missing or contradictory information, and noted any problems 
or concerns on the form. Saliva samples were stored at −20°C at the clinics until shipped to 
the CDC laboratory on dry ice.
Blood—Study personnel collected whole blood via venipuncture at the antecubital fossa, 
first completely filling 1 Tempus blood RNA tube (ThermoFisher Scientific/Applied 
Biosystems, Foster City, California) and then filling a PAX-gene blood DNA tube (Qiagen, 
Valencia, California). Immediately after each tube of blood was collected, it was vigorously 
shaken by hand for 10–20 seconds and placed upright in a wire rack at room temperature for 
2 hours. Blood samples in collection tubes were then stored at −20°C (upright in wire rack) 
until shipped to the CDC.
Sample size consideration
In stage 1, we aimed to enroll 450 patients in a 1-year timeframe using a standardized 
approach. Sample size was primarily constrained by budgets and the feasibility of the study 
management at each clinical site. On the basis of previous ME/CFS clinical studies, we 
anticipated a follow-up rate of 75%, resulting in a total of 338 patients for whom we would 
collect complete data (≥80% of valid data via instruments/forms) and who would be eligible 
for the follow-up of ME/CFS subjects at stage 2. Based on an effect size of 0.4, a minimum 
of 130 subjects were needed in the ill comparison group to achieve 90% power to detect the 
2-point difference in mean Multidimensional Fatigue Inventory sub-scale scores (16) and in 
the groups with ME/CFS and other illness to detect the 12-point differences in mean 36-Item 
Short Form Survey subscale scores (14, 15). A healthy control group of equal size was 
recruited for group comparisons of ME/CFS illness domain measures.
Data management
Coded data were delivered to the CDC’s Epidemiology, Data Management, and Analysis 
team via a secure file transfer protocol (FTP) site. Data formats included electronic data files 
or PDF files of scanned data collection forms/instruments. After completing quality control 
assessments of data collection and any additional required data entry, the team merged data 
into 1 master database for centralized storage, cleaning, data processing, and analysis. The 
team developed a standard protocol for data entry and data cleaning/editing, including 
checking out-of-range values, outliers, and missing data. Clinic personnel were contacted to 
attempt to resolve any missing or discordant data.
For data collected at multiple time points, such as awakening salivary cortisol and α-
amylase measures, quality control was performed by 1) using a subject matter expert review 
guide developed from previous CDC studies of ME/CFS and 2) applying statistical 
approaches, including descriptive statistics summaries and data visualization (e.g., lasagna 
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plots or heat maps). For instrument data, the scale scores were generated using the triangular 
validation approach: Scores were calculated by 2 independent programmers using different 
software and compared by a third person. (Programming codes developed for scoring are 
available upon request.) During the scoring process, internal consistency and skip patterns 
were checked. Overall, the internal consistency coefficients were equal to or greater than the 
reported values from the original source documents for each scale.
RESULTS
Stage 1 was completed in September 2013, with 471 study participants completing at least 
80% of each instrument and form. This exceeded target enrollment by 5%. Each of the 7 
clinics contributed 10%–16% of enrolled patients. Demographic characteristics of the 
ME/CFS patients are shown in Table 2. Overall, the mean age of patients was 48.2 years; 
73.9% were female, and 94.7% were white. Nearly all were insured (94.4%), but 74.9% 
were not working. Of those who were currently unemployed, 69.6% reported that they were 
disabled, and only 16.9% were currently receiving unemployment benefits. Regardless of 
current employment status, 72.6% of patients reported missing work or school because of 
their illness. The majority (77.0%) had a college education or more, and 56.1% were 
married. Patients had a mean body mass index (weight in kilograms divided by height in 
meters squared) of 26.6. The mean age at onset of illness was 38.4 years, and the mean 
duration of illness at the time of enrollment was 14.3 years. Overall, 65.4% of patients 
described a sudden onset of illness.
The proportions of patients who reported each symptom evaluated using the CDC Symptom 
Inventory are shown in Figure 1. Fatigue, postexertional malaise, and unrefreshing sleep 
were the 3 most-reported symptoms. As shown in Table 3, the mean number of reported CFS 
symptoms (from the 1994 case definition) was almost 6 (out of a possible 8), and the mean 
score (frequency × severity) for these symptoms was 55. Table 3 also summarizes the mean 
scores for each subscale of the 36-Item Short Form Survey and Multidimensional Fatigue 
Inventory, providing an indication of the extent of functional impairment and fatigue in this 
study sample at baseline. The 36-Item Short Form Survey subscales were transformed to a 
scale of 0–100, with lower scores indicating less function (more impairment). The mean 
scores on the Physical Role Functioning and Vitality subscales were the lowest, whereas 
those on the Emotional Role Functioning and Mental Health subscales were highest. The 
Multidimensional Fatigue Inventory subscales are scored from 0 to 20, with higher scores 
indicating more severe fatigue. Among the ME/CFS patients, general fatigue and physical 
fatigue were the 2 subscales with highest scores, and reduced motivation had the lowest 
score. For each measure, the scores were distributed broadly over a wide range, which 
indicates a large variation. As an example, the distribution of scores on the 36-Item Short 
Form Survey is shown in Figure 2, with the average values for the healthy controls enrolled 
to date shown as a comparison.
Collection of biospecimens was initiated in stage 2, with overall success. To date, more than 
90% of participants have provided blood and saliva samples. We chose collection methods 
that required minimal processing and handling at the clinics. The saliva collection required 
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frequent communication between the participants and clinic personnel for explanation of kit 
components and reminders before the clinic visit.
DISCUSSION
In the present article, we provide detailed information on the design of our multisite clinical 
investigation of ME/CFS. All data abstraction forms, questionnaires, and scoring methods 
are provided in the Web Appendix as a resource for other investigators. As future studies use 
and evaluate these data collection tools, we anticipate that a systematic approach to data 
collection and agreement on common data elements will emerge that will facilitate data 
sharing initiatives.
The Chronic Fatigue Initiative (CFI) Study shares some similarities with MCAM, but in the 
former, eligibility was determined based on case definition, and smaller numbers of patients 
with ME/CFS were enrolled (33). Inclusion of multiple clinics is important to increase 
geographic representation and identify differences between clinical practices. The success of 
the multisite infrastructure established with the partnership of study clinicians is indicated 
by the fact that enrollment data were collected on 471 ME/CFS patients, which exceeded the 
target by 5%. The rolling cohort design will allow collection of follow-up data, as well as 
enrollment of comparison groups (ill and healthy) and hard-to-reach ME/CFS patients (near 
onset and severely ill).
The data on frequency and severity of symptoms, extent of functioning, and fatigue of the 
patients enrolled in stage 1 demonstrate characteristic features of ME/CFS. As measured 
using the CDC Symptom Inventory, fatigue, postexertional malaise, and unrefreshing sleep 
are the most frequently reported symptoms. The 36-Item Short Form Survey and 
Multidimensional Fatigue Inventory subscale scores of ME/CFS patients document profound 
impairment from this illness and also show the relative preservation of emotional 
functioning and mental health. Scores on these and other instruments will be used to 
compare patients among clinics and to compare patients with the healthy and ill comparison 
groups that are being enrolled in subsequent stages of the study. A standardized approach to 
measuring ME/CFS will allow the extent of patient heterogeneity to be described and could 
contribute to being able to more reproducibly evaluate the similarities and differences in 
study populations that affect the ability to replicate findings.
Evaluating the performance of the patient-reported outcome measures will be helpful in 
developing recommendations for their use as outcome measures in clinical trials of ME/
CFS. Finally, the full range of phenotypic measures combined with biologic data (routine 
laboratory data and morning cortisol data) can allow us to begin the process of subgrouping 
patients. The DNA and RNA isolated from whole blood and the saliva will form the basis of 
a biorepository linked to epidemiologic data that can be used to address hypothesis-driven 
questions on etiology.
The most significant limitation of the present study is a consequence of its most significant 
strength. The partnering ME/CFS clinics are highly specialized (tertiary care) clinics where 
patients with more resources (economic and social) are more likely to be seen. For example, 
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uninsured patients, members of minority groups, and those with less education have not 
been well represented in the study sample to date. The study was conducted in English and 
required participants to read documents that were at an eighth grade reading level. 
Therefore, the study sample might not represent all ME/CFS patients.
The strength of this study’s design lies in the expertise of the clinicians who recruited 
patients. The clinicians each have 10 to more than 30 years of experience with diagnosing 
and caring for ME/CFS patients. This allows the participants’ self-reported measures of the 
major domains of illness (activity limitation, fatigue, sleep, pain, range of symptoms, and 
severity) to be evaluated based on expert clinical diagnosis, which is the best option in the 
absence of a gold standard. Using the same process to collect data on ill and healthy 
comparison groups will allow us to identify those measures with greatest specificity for 
ME/CFS diagnosis. Data on how expert physicians use pharmacologic and 
nonpharmacologic management and laboratory evaluations to care for their ME/CFS 
patients can be useful to describe current expert practice.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Percentages of patients with specific symptoms (based on the CDC Symptom Inventory for 
chronic fatigue syndrome) in stage 1, Multi-Site Clinical Assessment of Myalgic 
Encephalomyelitis/Chronic Fatigue Syndrome, 2012–2013. The CDC Symptom Inventory 
asks about symptoms experienced in the past month. Symptoms that have been present for 
less than 6 months were assigned a score of 0 and were not included. A frequency of 1 
indicates a little of the time, and a frequency of 2 indicates some of the time. A severity of 1 
indicates very mild or mild, and a severity of 2.5 indicates moderate. The gray bars indicate 
the percentages of patients who reported the specified symptom with both frequency and 
severity of 2 or greater. The black bars indicate the percentages of patients reporting that 
symptom with frequency and severity of 1 or greater. Symptoms are listed by increasing 
percentages of patients who reported symptoms with a frequency and a severity of at least 2.
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Figure 2. 
Distribution of 36-Item Short Form Survey Subscale (Short Form-36) scores in patients with 
myalgic encephalomyelitis/chronic fatigue syndrome in stage 1, Multi-Site Clinical 
Assessment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome, 2012–2013. The 
boxplots display the 5-number summary: minimum, first quartile, median, third quartile, and 
maximum. The central rectangle spans from the first quartile to the third quartile (the 
interquartile range), a segment inside the rectangle shows the median, and the dotted lines 
(sometimes referred to as whiskers) are extended to the extrema of the distribution in the 
data set. The mean value in each boxplot is indicated by a diamond. The circles indicate 
outliers, and the thick black bars indicate the means among the 213 healthy controls with 
data as of September 2015 (collected 2013–2015). Lower scores indicate more disability. 
Adapted from the Centers for Disease Control and Prevention (34).
Unger et al. Page 14
Am J Epidemiol. Author manuscript; available in PMC 2018 April 15.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Unger et al. Page 15
Table 1
Questionnaires Used in the Multi-Site Clinical Assessment of Myalgic Encephalomyelitis/Chronic Fatigue 
Syndrome
Questionnaire Recall Period Description Reference
CDC Symptom Inventory Past month Assessment of the occurrence, frequency, and intensity of 
symptoms common in CFS and other fatiguing illnesses
13
Medical Outcomes Study 36-Item Short 
Form Survey
Past 4 weeks General indicator of function and wellbeing in 8 areas 
(physical activities, social activities, usual role activities, 
bodily pain, general mental health, limitations due to 
emotional problems, vitality (energy and fatigue), and general 
health perception)
14, 15
Multidimensional Fatigue Inventory “Lately” (less 
than a week)
Self-reported measure of fatigue covering dimensions of 
general fatigue, physical fatigue, mental fatigue, reduced 
motivation, and reduced activity
16
DePaul Symptom Questionnaire (partial) Past 6 months Assessment of the occurrence, frequency, and intensity of 
symptoms common in CFS and other fatiguing illnesses; only 
items not covered in other questionnaires are included
11
PROMIS Fatigue Short Form V1.0 Past 7 days Seven self-reported items selected to represent content in the 
PROMIS fatigue item bank; measures of fatigue were 
designed for use in wide variety of illnesses
17, 18
PROMIS Sleep Disturbance 8-Item Short 
Form
Past 7 days Eight self-reported items to assess perception of sleep quality, 
sleep depth, and restoration associated with sleep over the 
past 7 days, including questions about difficulties getting to 
sleep, staying asleep, adequacy of sleep and satisfaction with 
sleep
19–21
PROMIS Sleep-Related Impairment Short 
Form V1.0
Past 7 days Eight self-reported items to assess perception of alertness, 
sleepiness, and tiredness during usual waking hours and 
functional impairment associated with sleep problems or 
impaired alertness over the past 7 days
19–23
PROMIS Pain Behavior Short Form Past 7 days Seven self-reported measures of external manifestations of 
pain over the past 7 days, including observable displays 
(sighing, crying), pain severity behavior (resting, guarding, 
facial expressions, asking for help), and verbal reports of pain
20–22
PROMIS Pain Interference Short Form Past 7 days Six self-reported measures of the consequences of pain on 
social, cognitive, emotional, physical, and recreational 
activities, as well as on sleep and enjoyment of life, over the 
past 7 days
20, 21, 23
Brief Pain Inventory (long form) In the past week Measures intensity of pain and interference with activities; 
records location of pain and pain descriptor
24
Health-Related Quality of Life Past 30 days Four questions to assess perceived sense of well-being, self-
rated health, recent number of days when mental or physical 
health was not good, and days when activity was limited 
because of health
25
Illness Impact Questionnairea Past 7 days Adapted from Fibromyalgia Impact Questionnaire Revised; 
assesses pain, fatigue, stiffness, poor sleep, depression, poor 
memory, anxiety, tenderness, poor balance, and environment 
sensitivity, with subscales for symptoms, function, and overall 
impact
26, 27
Patient Health Questionnaire depression 
scaleb
Past 2 weeks Comparable to Patient Health Questionnaire-9 in diagnosing 
depressive disorders; omits suicidal ideation
28, 29
Generalized Anxiety Disorder 7-Item 
Scaleb
Past 2 weeks Seven items developed to diagnose generalized anxiety and 
screens for panic, social anxiety, and posttraumatic stress 
disorder. Score cutpoints for mild, moderate, and severe 
anxiety developed
30, 31
Self-Rating Depression Scaleb Recently Quantifies the severity of current major depression in 20 items 32
Abbreviations: CDC, Centers for Disease Control and Prevention; CFS, chronic fatigue syndrome; PROMIS, Patient Reported Outcome 
Measurement Information System.
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aWe adapted the Fibromyalgia Impact Questionnaire by replacing “fibromyalgia” with “illness” throughout the questionnaire.
bOnly administered at the clinic.
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Table 2
Demographic Characteristics of Patients in Stage 1, Multi-Site Clinical Assessment of Myalgic 
Encephalomyelitis/Chronic Fatigue Syndrome, 2012–2013
Characteristic No. %
Age, yearsa
    18–29 53 11.3
    30–39 57 12.1
    40–49 104 22.1
    50–59 177 37.6
    ≥60 80 17.0
Female sex 384 73.9
Race
    White 442 94.7
    Black/African-American 6 1.3
    All others 19 4.1
Marital status
    Married/committed 259 56.1
    Previously married 76 16.5
    Never married 127 27.5
Employment
    Full-time 66 14.2
    Part-time 51 10.9
    Not working 349 74.9
Had insurance 435 94.4
Educational level
    Less than high school 4 0.9
    High school 101 22.1
    College 181 39.6
    Postcollege 171 37.4
a
The mean age was 48.24 (standard error, 0.59) years.
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Table 3
Measures of Illness in Patients in Stage 1, Multi-Site Clinical Assessment of Myalgic Encephalomyelitis/
Chronic Fatigue Syndrome, 2012–2013
Scale and Subscale Score, mean(SE)
SF-36 Physical Functioninga 37.98 (1.39)
SF-36 Physical Role Functioninga 4.00 (0.91)
SF-36 Bodily Paina 39.14 (1.42)
SF-36 General Health Perceptionsa 25.24 (0.96)
SF-36 Vitalitya 17.53 (1.04)
SF-36 Social Role Functioninga 26.32 (1.40)
SF-36 Emotional Role Functioninga 72.73 (2.49)
SF-36 Mental Healtha 67.19 (1.24)
MFI-20 General Fatigueb 18.27 (0.14)
MFI-20 Physical Fatigueb 17.44 (0.17)
MFI-20 Reduced Activityb 16.08 (0.21)
MFI-20 Reduced Motivationb 11.81 (0.25)
MFI-20 Mental Fatigueb 14.56 (0.24)
CDC Symptom Inventory: no. of CFS symptomsc 5.89 (0.11)
CDC Symptom Inventory: CFS symptom scored 55.02 (1.38)
Abbreviations: CFS, chronic fatigue syndrome; MFI-20, Multidimensional Fatigue Inventory; SF-36, 36-Item Short Form Survey.
aSF-36 scores range from 0–100, with higher scores indicating better health.
b
MFI-20 scores range from 4–20, with higher scores indicate a higher level of fatigue.
c
The score for number of CFS symptoms ranges from 0–8, with higher scores indicating more symptoms lasting for 6 months or longer.
d
The 8 CFS symptom score ranges from 0–128, with higher scores indicating higher severity of symptoms.
Am J Epidemiol. Author manuscript; available in PMC 2018 April 15.
